2014
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJ, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014, 515: 577-581. PMID: 25428507, PMCID: PMC4279952, DOI: 10.1038/nature13988.Peer-Reviewed Original Research
2013
Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy
Vesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Annals Of The New York Academy Of Sciences 2013, 1284: 1-5. PMID: 23651186, PMCID: PMC3648872, DOI: 10.1111/nyas.12105.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsImmune systemTumor-specific antigensHuman cancer patientsTumor-promoting actionsNascent tumor cellsAntitumor immunityTumor immunityCancer immunosurveillanceChronic inflammationPersonalized cancer therapyImmunogenic variantsCancer immunotherapyCancer patientsCancer immunoeditingT cellsAnimal modelsTumor variantsTumor progressionTumor cellsCancer cellsImmunityCancer therapyCancerAntigenImmunoselection